Our achievements. Our accomplishments. Our impact.



  • Public Engagement

    The Stem Cell Network has elevated the level of public discourse and understanding about stem cells in Canada by engaging Canadians in artistic, accessible and innovative explorations of emerging issues in the field and by becoming an active and respected presence online.

    READ STORY

  • Till & McCulloch Meetings

    The Stem Cell Network’s Annual General Meeting, which metamorphosed into the Till & McCulloch Meetings, is a one-of-a-kind venue for trainees and young scientists to network and gain experience in the competitive field of regenerative medicine.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Cutting-Edge Skills Development

    The Stem Cell Network worked diligently to identify key areas where enhanced training, provided on a national scale, would have direct benefits on research outcomes and also for Canada’s future scientists and clinicians.

    READ STORY

  • Establishing a Community

    By prioritizing multidisciplinary research partnerships among stem cell researchers across Canada, the Stem Cell Network integrated the country’s previously fractured landscape into a comprehensive and globally respected research community.

    READ STORY

  • Blood Stem Cell Expansion

    Over more than a decade of targeted funding, the Stem Cell Network harnessed the strength of world-leading Canadian researchers to develop technologies to increase quantities of blood stem cells for expanded therapeutic use and to overcome a significant hurdle in the delivery of cell-based treatments to patients.

    READ STORY